Article
Industry Challenges Contribute to Financial Toxicity
In this third panel discussion from ONS’s Health Policy Summit in Washington DC, Alan Balch, PhD, Patient Advocate Foundation chief executive officer, Mike Ybarra, MD, FAAEM, FACEP, vice president of medical affairs for the Pharmaceutical Research Manufacturers Association, and Jeannine Walston, a 20-year brain cancer survivor and patient advocate, discuss the challenges of tackling financial toxicity from an industry perspective, how nurses can advocate for patient resources, and much more.
Related Topics
You May Also Like
Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Article